Image
Cybin Inc. (NEO: CYBN) (NYSE:CYBN), a biopharmaceutical company focused on advancing “psychedelics into therapeutics”, just announced a monumental milestone toward advancing CYB003 into clinical development. CYB003 is a deuterated psilocybin analog designed to achieve less variability, faster onset of action, shorter duration of effect and potentially better tolerability than pure psilocybin. CYB003 has the potential to effectvely treat major depressive disorder (MDD) and alcohol use disorder (AUD).
On May 26, Cybin (NEO: CYBN) (NYSE:CYBN) announced that it had submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer .
For further details see:
Cybin Submits IND Application to FDA for CYB003 Phase 1/2a Clinical Trial